JDRF and Sanofi have announced a $4.6 million, three-year initiative to expand development of insulins that require fewer injections and dermal patch-delivered insulin. In both cases, it’s hoped that the insulin delivered will be able to respond automatically to changes in blood sugar levels and other body metabolism signals.

Read more